Bezabhe Woldesellassie M, Bereznicki Luke R, Radford Jan, Wimmer Barbara C, Curtain Colin, Salahudeen Mohammed S, Peterson Gregory M
School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS, Australia.
Launceston Clinical School, Tasmanian School of Medicine, University of Tasmania, Hobart, TAS, Australia.
Front Pharmacol. 2021 Mar 23;12:586370. doi: 10.3389/fphar.2021.586370. eCollection 2021.
Appropriate use of oral anticoagulants (OACs) reduces the risk of stroke in patients with atrial fibrillation (AF). The study characterized the prescribing of OACs in people with AF in the Australian primary care setting over 10 years. Retrospective population study. We performed 10 sequential cross-sectional analyses of patients with a recorded diagnosis of AF between 2009 and 2018 using national general practice data. The proportion of patients with AF who were prescribed an OAC based on their stroke risk was examined. The primary outcome was the proportion of high stroke risk patients who were prescribed an OAC over a decade. The secondary outcome was variation in OAC prescribing among general practices. The sample size of patients with AF ranged from 9,874 in 2009 to 41,751 in 2018. The proportion who were prescribed an OAC increased from 39.5% (95% CI 38.6-40.5%) in 2009 to 52.0% (95% CI 51.5-52.4%) in 2018 ( for trend < 0.001). During this time, the proportion of patients with AF and high stroke risk who were prescribed an OAC rose from 41.7% (95% CI 40.7-42.8%) to 55.2% (95% CI 54.7-55.8%; for trend < 0.001) with the direct-acting oral anticoagulants accounting for over three-quarters of usage by 2018. There was substantial variation in OAC prescribing between general practices. In 2018, the proportion of moderate to high stroke risk patients who were prescribed an OAC was 38.6% (95% CI 37.2-40.1%) in the lowest practice site quintiles and 65.6% (95% CI 64.5-66.7%) in the highest practice site quintiles. Over the 10 years, OAC prescribing in high stroke risk patients with AF increased by one-third. There was considerable variation in OAC prescribing between general practices.
合理使用口服抗凝剂(OACs)可降低心房颤动(AF)患者的中风风险。本研究对澳大利亚初级医疗环境中房颤患者10年来的OACs处方情况进行了特征描述。回顾性人群研究。我们利用全国全科医疗数据,对2009年至2018年间记录有房颤诊断的患者进行了10次连续的横断面分析。研究了根据中风风险开具OACs处方的房颤患者比例。主要结局是在十年期间开具OACs处方的高中风风险患者比例。次要结局是全科医疗中OACs处方的差异。房颤患者样本量从2009年的9874例到2018年的41751例不等。开具OACs处方的比例从2009年的39.5%(95%CI 38.6 - 40.5%)增至2018年的52.0%(95%CI 51.5 - 52.4%)(趋势P<0.001)。在此期间,开具OACs处方的房颤高危中风患者比例从41.7%(95%CI 40.7 - 42.8%)升至55.2%(95%CI 54.7 - 55.8%;趋势P<0.001),到2018年直接口服抗凝剂的使用占比超过四分之三。全科医疗之间的OACs处方存在很大差异。2018年,中风风险中到高的患者中,在最低的实践地点五分位数中开具OACs处方的比例为38.6%(95%CI 37.2 - 40.1%),在最高的实践地点五分位数中为65.6%(95%CI 64.5 - 66.7%)。在这10年中,房颤高危中风患者的OACs处方增加了三分之一。全科医疗之间的OACs处方存在相当大的差异。